← Eichor
Study identifier: NCT07413835 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

Condition: Refractory Myasthenia Gravis  ·  Sponsor: The Affiliated Hospital of Xuzhou Medical University

PhaseNA
Planned participants6
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.

This description comes directly from the study's public registry record.

Talk to the study team

Yong Zhang  ·  86-0516-85802193  ·  zy20037416@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Affiliated Hospital of Xuzhou Medical UniversityXuzhou, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07413835